CD8A and neoplasm: Magrì et al. (100) demonstrated that high-dose VC, when paired with immunotherapy, can slow tumor growth in melanoma, colorectal, pancreatic, and breast cancers by promoting T-cell infiltration into the tumor microenvironment and enhancing CD8+ T cell cytotoxicity.